TP53 and cancer: To investigate whether that the concomitant inactivity of Sam68 and TP53 arrested cancer cell growth, TP53 wild-type MCF7 cell lines were engineered by using CRISPR/Cas9 technology to introduce a TP53 mutation (R248Q).